Illumina advances preventive genomics through strategic consortium with Veritas Genetics Illumina (NASDAQ: ILMN) on March 16, 2026 announced a strategic consortium with Veritas Genetics Powered By Fuze Health to integrate whole-genome sequencing into preventive care via health plans. The collaboration combines Illumina sequencing and informatics with Veritas patient-ready reporting to enable earlier risk detection, integrated care pathways, and a consented clinical-genomics dataset.The program targets hereditary cancer, cardiometabolic risk, and medication response, and includes sample collection, confirmatory testing, counseling, and industry data partnerships.

#ILMN Illumina advances preventive genomics through strategic consortium with Veritas Genetics

www.stocktitan.net/news/ILMN/illumina-advan...

Gilbert Cisneros - Integrity Index View Gilbert Cisneros's political integrity grade, campaign financing, and conflicts of interest.

Rep. Gilbert Cisneros (D-CA) disclosed 60 trades:
Traded: Feb 10 | Disclosed: Mar 9

Bought: $ZTS ($1K-$15K), $FSV ($15K-$50K), $AMD ($1K-$15K), $OXY ($1K-$15K), $ILMN ($1K-$15K), $CTRA ($1K-$15K), $KMI ($1K-$15K), $AMZN ($1K-$15K), $XOM ($50K-$100K), $COP ($1K-$15K), $EQT ($1K-$15K), $STE ($1K-$...

Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering Illumina (NASDAQ: ILMN) and NashBio announced expansion of the Alliance for Genomic Discovery on March 5, 2026: the core dataset grows to 312,000 whole genomes with longitudinal clinical data and a new multiomic initiative will add 50,000 whole genomes paired with proteomic data using Illumina Protein Prep.Regeneron Genetics Center joins as the tenth member, and GSK is among the first participants in the proteomics expansion. Illumina's recent acquisition of SomaLogic proteomics technologies is cited as enabling the multiomic effort.

#ILMN Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

www.stocktitan.net/news/ILMN/alliance-for-g...

Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology Illumina (NASDAQ: ILMN) announced that CMS will reimburse its FDA-approved TruSight™ Oncology Comprehensive (TSO Comprehensive) test at $2,989.55 per test under PLA code 0543U, effective January 1, 2026. The decision places TSO Comprehensive on the Clinical Laboratory Fee Schedule and establishes a predictable reimbursement pathway for Medicare beneficiaries. Illumina says broader reimbursement will enable more labs to provide in-house comprehensive genomic profiling (CGP) and expand access to precision oncology across hospitals, networks, and regional labs. Illumina also noted clinical markets drove growth, with ~60% of sequencing consumables revenue from clinical customers in 2025.

#ILMN Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology

www.stocktitan.net/news/ILMN/illumina-secur...

Illumina Unveils the Billion Cell Atlas to Accelerate AI-Powered Drug Discovery Illumina, Inc. (Nasdaq: ILMN) today announced the launch of the Illumina Billion Cell Atlas, a landmark genomic data resource designed to drive the next generat

#Illumina ( NASDAQ: #ILMN) Unveils the Billion Cell Atlas to Accelerate AI-Powered Drug Discovery
prismmarketview.com/illumina-unv...

Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery Illumina (NASDAQ: ILMN) introduced the Illumina Billion Cell Atlas on January 13, 2026, a genome‑wide genetic perturbation dataset built to accelerate AI‑driven drug discovery.The first tranche targets 1 billion individual cells across 200+ disease‑relevant cell lines, using CRISPR to perturb ~20,000 genes. Illumina plans a 5 billion cell resource over three years and expects to generate ~20 petabytes of single‑cell transcriptomic data within a year, processed via DRAGEN and hosted on Illumina Connected Analytics. AstraZeneca, Merck, and Eli Lilly are founding participants under an alliance framework.

#ILMN Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery

www.stocktitan.net/news/ILMN/illumina-intro...

Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 SAN DIEGO, Jan. 13, 2026/ PRNewswire/-- Illumina, Inc. today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025 ahead of its presentation at the 44th Annual J.P. Revenue of approximately $1.155 billion, up 5% from Q4 2024 Ex- China revenue of approximately $1.100 billion, up 7% from Q4 2024 GAAP diluted EPS of $2.14 to $2.17...

#ILMN Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025

www.stocktitan.net/news/ILMN/illumina-annou...

Just In: ( NASDAQ: #ILMN ) /C O R R E C T I O N -- MyOme, Inc/

Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually Illumina (NASDAQ: ILMN) announced a collaboration and strategic investment in MyOme to support MyOme's Proactive Health (MPH) Trial and expand clinical genomics products. The MPH Trial aims to enroll beginning in 2026 and will test whole‑genome sequencing (WGS) plus MyOme's AI‑integrated risk models (IRMs) for earlier detection and prevention across cancers, cardiometabolic and rare diseases. Health economic modeling cited in the announcement estimates potential U.S. cost savings of more than $200 billion annually if WGS+IRM adoption is broad. The deal also notes continued financing support from partners including Natera, Sequoia Capital and The Duquesne Family Office.

#ILMN Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually

www.stocktitan.net/news/ILMN/illumina-and-m...

Illumina Responds to Positive Updates from Chinese Ministry of Commerce SAN DIEGO, Nov. 5, 2025/ PRNewswire/-- The Chinese Ministry of Commerce today announced it will lift the export ban on Illumina, Inc., which had been in place since March 4, 2025. For two decades, Illumina has been proud to partner with customers in China to advance genomics and improve human health. "I want to thank our customers for their trust and support, and our team in...

#ILMN Illumina Responds to Positive Updates from Chinese Ministry of Commerce

www.stocktitan.net/news/ILMN/illumina-respo...

#ILMN has a ton of value in the world of applying AI to biotech + medicine, but Wall Street has largely ignored that value as the stock has been clobbered by China issues, management changes, operational miscues, etc.

That could be changing. This quarter feels like an inflection point.

#ILMN Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025

www.stocktitan.net/news/ILMN/illumina-repor...

Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights Illumina (NASDAQ: ILMN) on October 15, 2025 announced its 5-base solution for simultaneous genomic variant detection and DNA methylation profiling from a single sample. The offering uses proprietary 5-base chemistry and DRAGEN algorithms to enable dual-omic analysis with reduced complexity and cost.Two kits are commercially available: Illumina 5-Base DNA Prep (whole-genome) and 5-Base DNA Prep with Enrichment (targeted). Both detect methylation at single-base resolution and are compatible with NovaSeq Systems and NextSeq 2000. Over 50 early testers participated, and a London Health Sciences Centre researcher will present validation data at ASHG on October 15, 2025.

#ILMN Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights

www.stocktitan.net/news/ILMN/illumina-fuels...

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ERO 5.4x
2. #TME 3.5x
3. #ILMN 3.2x
4. #PLAY 3.2x
5. #VLY 3.0x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ERO, #ILMN, #PLAY, #VLY, #TRGP

#OptionFlow #OptionsTrading #Trading

Major Cancer Testing Breakthrough: Illumina Teams with Global Pharma Giants on KRAS Mutation Detection Illumina partners with pharmaceutical companies to develop companion diagnostics for KRAS biomarker on TruSight Oncology platform, advancing precision cancer treatment matching across tumor types.

#ILMN Illumina advances personalized cancer care with new pharma development partnerships

www.stocktitan.net/news/ILMN/illumina-advan...

Illumina: A 5.2 Rating Amid Challenges and Opportunities | The Motley Fool

#ILMN #6c28cc32-7ba9-4a7b-8914-22344f9e90cc #investing

Origin | Interest | Match

Illumina Beats Q2 Earnings Expectations, Boosts 2025 Outlook Despite Revenue Dip Illumina raises FY25 EPS guidance to $4.45-$4.55, announces SomaLogic acquisition amid margin expansion. See detailed Q2 performance metrics.

#ILMN Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

www.stocktitan.net/news/ILMN/illumina-repor...

Illumina Achieves Major ESG Milestones: 1.4 Billion Lives Now Covered for Genomic Testing, Sustainability Goals Surpassed Discover how Illumina expanded genomic testing coverage to 1.4B people while achieving 80% packaging reduction. New sustainability milestones revealed. See full impact.

#ILMN lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics

www.stocktitan.net/news/ILMN/lllumina-relea...

Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis Illumina (NASDAQ: ILMN) has unveiled PromoterAI, a groundbreaking AI algorithm that accurately identifies pathogenic regulatory genetic variants in noncoding regions of the human genome. According to a study published in Science, this technology discovered regulatory variants in promoter segments that contribute up to 6% of genetic causes of rare diseases.PromoterAI analyzes noncoding promoter regions, which are crucial for gene transcription and comprise over 98% of the genome. When combined with whole-genome sequencing (WGS), this AI tool could improve rare disease diagnosis rates, which currently stand at only 30% with exome sequencing. The algorithm, together with Illumina's other AI tools (PrimateAI-3D and SpliceAI), effectively doubles the diagnostic yield compared to using protein-truncating variants alone.The technology is now available through Illumina Connected Software and DRAGEN™ secondary analysis, with precomputed scores freely available for academic and noncommercial research.

#ILMN Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis

www.stocktitan.net/news/ILMN/illumina-unvei...

Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies Illumina (NASDAQ: ILMN) announced an expansion of its clinical oncology portfolio with two key developments. First, their TruSight™ (TSO) Comprehensive test, the first FDA-approved distributable comprehensive genomic profiling IVD kit with pan-cancer CDx claims, has gained broad payer reimbursement including Medicare and most commercial health plans. UofL Health became the first customer to implement the test. The test has also received regulatory approval in Japan.Second, Illumina partnered with Pillar Biosciences to offer Pillar oncoReveal CDx, an IVD kit for detecting genetic variations in 22 genes for solid tumor patients. The test recently received nationwide Medicare coverage, making it accessible to over 66 million Medicare beneficiaries in the US.

#ILMN Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies

www.stocktitan.net/news/ILMN/illumina-expan...

Insider Buying Week 05-16-25 The Best Insider Buy/Sell Ratio in a Year The busiest week we’ve seen in some time.  In fact, it’s so busy that I would venture to say that […]

based technologies for genetic and genomic analysis across global markets.
Could Illumina's genomic leadership position them for significant growth as geopolitical tensions ease? What's your view on the potential reunion with Grail?
www.theinsidersfund.com/2025/05/insi...
#NotInvestmentAdvice #ILMN

Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications Illumina (NASDAQ: ILMN) has launched DRAGEN v4.4, an enhanced secondary analysis software solution featuring significant improvements in accuracy and functionality. Key highlights include a 30% improvement in structural variant calling accuracy and a 20% boost in SNV and indel calling accuracy. The update introduces preconfigured oncology applications for clinical research, enhanced multiomics pipelines, and AWS F2 support for faster processing. The University Hospital of Tübingen has selected DRAGEN for a pioneering study to evaluate clinical utility in whole-genome germline testing. The software's new features include push-button analysis for oncology workflows, support for new multiomics assays, and improved cloud analysis capabilities. This release builds on DRAGEN's established leadership in variant calling accuracy, as validated in a peer-reviewed Nature Biotechnology study from October 2024.

#ILMN Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications

www.stocktitan.net/news/ILMN/illumina-drage...

Illumina Reports Financial Results for First Quarter of Fiscal Year 2025 Illumina (ILMN) reported Q1 2025 financial results with core revenue of $1.04 billion, down 1% year-over-year. The company posted GAAP operating margin of 15.8% and non-GAAP operating margin of 20.4%. Q1 GAAP diluted EPS was $0.82, while non-GAAP diluted EPS reached $0.97. Cash flow from operations was $240 million with free cash flow of $208 million. The company revised its FY2025 guidance downward, now expecting core revenue to decline 1-3% on a constant currency basis. Revenue outside Greater China is projected to grow 0-2%, while Greater China revenue is expected at $165-185 million. The company faces $85 million in tariff-related costs, impacting operating margin by 125 bps and EPS by $0.25. Non-GAAP operating margin guidance was lowered to 21.5-22.0% from 23%, with EPS guidance reduced to $4.20-4.30 from $4.50.

#ILMN Illumina Reports Financial Results for First Quarter of Fiscal Year 2025

www.stocktitan.net/news/ILMN/illumina-repor...

Earnings to watch
#CVNA #MCHP #TXRH #UBER #FTS #AKAM #EA #GEN #CDW #ILMN #RIVN #GOGO #KBR #YELP #HRB #DAY #F #PAYC #FANG #CF #TEVA #WOLF #PLNT #QLYS #COP #INTA #POST #AKAM #INFA #ZBRA #PAY #MAR #TTD #UPST #CV #NET #YELP #DASH #COIN #DUK #FVRR #GFS #HUBS #SWKS #FNV #OXY #CDW #CPNG #TTD

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#LKQ, #FNGR, #HAIN, #DAN, #ILMN

#OptionFlow #OptionsTrading #Trading

Game-Changing Partnership: How Illumina and Tempus Are Revolutionizing Precision Medicine With AI Strategic alliance combines advanced AI with genomic testing to expand precision medicine beyond cancer into cardiology, neurology, and immunology. Full impact analysis inside.

#ILMN #TEM Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

www.stocktitan.net/news/ILMN/illumina-and-t...

There may be a buying opportunity for #ilmn

Illumina's Massive 250K Genome Project Breakthrough Accelerates Drug Development Success Illumina completes landmark genomic sequencing project 2 years early, partnering with 8 biopharma companies to unlock novel drug targets in autoimmune and metabolic diseases.

#ILMN Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery

www.stocktitan.net/news/ILMN/alliance-for-g...